A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
for Alzheimer Disease
32 locations incl. Scottsdale
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 55 - 90
Code: NCT07011732·Phase 3·Recruiting·Listed Jun 2025